A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

Introduction: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptable safety profile. The aim of this report was to provide long-term data and evaluate potential benef...

Full description

Bibliographic Details
Main Authors: Zhenggang Ren, Shukui Qin, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Ping Yan, Jianjun Zou
Format: Article
Language:English
Published: Karger Publishers 2021-06-01
Series:Liver Cancer
Subjects:
camrelizumab
hepatocellular carcinoma
long-term follow-up
Online Access:https://www.karger.com/Article/FullText/516470

Internet

https://www.karger.com/Article/FullText/516470

Similar Items